Comparing the current results to its competitors, Tela Bio Inc reported Revenue increase in the 2 quarter 2026 by 0.97 % year on year. The revenue growth was below Tela Bio Inc 's competitors' average revenue growth of 12.44 %, achieved in the same quarter.
Tela Bio Inc 's Comment on Competition and Industry Peers
The company operates in a competitive industry with larger competitors. Its products, including OviTex and OviTex PRS, compete with biologic and resorbable synthetic mesh products. In a non-human primate comparative study, OviTex devices demonstrated better preservation of original shape and less contraction compared to biologic and synthetic mesh. The BRAVO recurrence rate for OviTex is among the lowest reported in published studies involving biologic or resorbable synthetic mesh competitors in similar high-risk patient cohorts. The company relies heavily on Aroa as the exclusive contract manufacturer for OviTex and OviTex PRS. Identified risks include potential intellectual property disputes, regulatory challenges, and supply chain issues. The company seeks to enhance its product offerings and expand indications to maintain its competitive position.
With modest revenue growth of 0.97 % within Overall company, Tela Bio Inc failed to increase sales with the same pace, like most of company's peers within this division. << More on TELA Market Share.
*Market share is calculated based on total revenue.
March 31, 2025
Revolutionizing Reconstructive Surgery: TELA Bio Launches Larger OviTex PRS Options, Outshining the Competition In the ever-evolving world of medical technology, innovation isn’t just a buzzword; it’s a necessity. TELA Bio Inc. is stepping up to meet this demand head-on with the announcement of the U.S. commercial launch of larger sizes of its OviTex PRS product, a powerful addition to the plastic and reconstructive surgery toolkit. This moment marks not only a significant advancement in the capacity of human acellular dermal matrix products but also positions TELA Bio at the forefront of a competitive industry striving for excellence.The OviTex PRS portfolio now boasts the largest offerings available in...
August 9, 2024
In a strategic move to bolster its team and potential market capabilities, TELA Bio, Inc. (NASDAQ: TELA) announced the approval of inducement grants of restricted stock units (RSUs) for nine newly-hired employees. This announcement, made on August 9, 2024, highlights the company’s commitment to attracting top talent to its commercial-stage medical technology pursuit, focusing on innovative solutions for soft-tissue reconstruction. Key Details:1. Nature of Grants : The inducement grants consist of 16,000 RSUs, which were approved by the Compensation Committee of TELA Bio’s Board of Directors. Each RSU represents a promise to deliver shares of common stock in the future, typically contingent upon continui...
Apyx Medical Corporation follows a business model that centers around the development, manufacturing, and marketing of medical devices used in the field of aesthetics and surgical markets. The company focuses on creating innovative products that improve patient outcomes and enhance the effectiveness of surgical procedures. Apyx Medical Corporation sells its devices primarily through a direct sales force in the United States, while utilizing a combination of direct sales representatives and distributors in international markets.
Stryker Corps business model focuses on innovation in medical technologies and devices, specializing in areas such as orthopedics, surgical equipment, and neurotechnology, to enhance patient care and improve outcomes in the healthcare industry.
Zimmer Biomet Holdings Inc operates as a global leader in musculoskeletal healthcare, focusing on the design, manufacture, and marketing of innovative medical devices for joint replacement, sports medicine, spine, and dental implants. Their business model emphasizes improving patient outcomes and advancing the field through advanced surgical products and solutions targeted at healthcare professionals worldwide.
Axogen Inc is a medical technology company specializing in the development and commercialization of products for peripheral nerve reconstruction. Their business model focuses on providing innovative solutions to surgeons and patients by offering a comprehensive portfolio of nerve repair technologies and services. Through partnerships with healthcare providers, Axogen aims to enhance patient outcomes and improve the quality of life for those suffering from peripheral nerve injuries.
Integra Lifesciences Holdings Corp's business model revolves around developing, manufacturing, and selling medical devices and instruments to healthcare providers.
Sources:
Tela Bio Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Tela Bio Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
